<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00016133</url>
  </required_header>
  <id_info>
    <org_study_id>INTRACEL-ASI-2002</org_study_id>
    <secondary_id>CDR0000068597</secondary_id>
    <nct_id>NCT00016133</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Stage II or Stage III Colon Cancer That Has Been Removed During Surgery</brief_title>
  <official_title>A Non-Randomized Multicenter Phase I/II Study Of Active Specific Immunotherapy In Patients With Stage II and Stage III Colon Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intracel</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from a patient's white blood cells and tumor cells may make the body&#xD;
      build an immune response to kill tumor cells. Drugs used in chemotherapy use different ways&#xD;
      to stop tumor cells from dividing so they stop growing or die. Combining vaccine therapy with&#xD;
      chemotherapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy combined with&#xD;
      leucovorin and fluorouracil in treating patients who have undergone surgery to completely&#xD;
      remove stage II or stage III colon cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine safety and immunogenicity of adjuvant autologous tumor cell vaccine in&#xD;
           patients with completely resected stage II or III adenocarcinoma of the colon.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to disease stage (II&#xD;
      vs III).&#xD;
&#xD;
      Beginning 28-35 days after total surgical resection, patients receive adjuvant autologous&#xD;
      tumor cell vaccine intradermally once weekly for 3 vaccinations. The first 2 vaccinations&#xD;
      also contain BCG. Patients with stage II disease receive a fourth vaccination 6 months after&#xD;
      surgical resection.&#xD;
&#xD;
      Beginning 10-17 days after the third vaccination, patients with stage III disease receive&#xD;
      adjuvant leucovorin calcium IV and fluorouracil IV on days 1-5. Chemotherapy continues every&#xD;
      28-35 days for a total of 6 courses. These patients also receive a fourth vaccination 1 month&#xD;
      after the completion of chemotherapy.&#xD;
&#xD;
      Patients are followed at 90 days and 6 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2001</start_date>
  <completion_date type="Actual">August 2004</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCG vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous tumor cell vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed stage II or III primary adenocarcinoma of the colon&#xD;
&#xD;
               -  Completely resected within the past 28-35 days, at which time tumor tissue is&#xD;
                  harvested for vaccine production&#xD;
&#xD;
               -  No residual or metastatic disease&#xD;
&#xD;
          -  No more than 1 malignant invasive primary colon cancer&#xD;
&#xD;
          -  No tumor originating in the rectum (i.e., inferior tumor margin must not be at or&#xD;
             below the peritoneal reflection)&#xD;
&#xD;
          -  No perforated tumors&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  21 to 85&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  WHO 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC greater than 4,000/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin greater than 10.0 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  SGOT normal&#xD;
&#xD;
          -  Alkaline phosphatase normal&#xD;
&#xD;
          -  No severe hepatic disease that would preclude study&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 1.5 times upper limit of normal&#xD;
&#xD;
          -  No severe renal disease that would preclude study&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No prosthetic cardiac valves&#xD;
&#xD;
          -  No recent vascular prosthesis&#xD;
&#xD;
          -  No postsurgical cardiovascular complication&#xD;
&#xD;
          -  No severe cardiovascular disease that would preclude study&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No postsurgical pulmonary complication&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No insulin-dependent diabetes mellitus&#xD;
&#xD;
          -  No severe systemic disease that would preclude study&#xD;
&#xD;
          -  No congenital or acquired immune deficiency disease&#xD;
&#xD;
          -  No history of chronic ulcerative colitis, Crohn's disease, Gardner's syndrome, or&#xD;
             Turcot's syndrome&#xD;
&#xD;
          -  No ileus&#xD;
&#xD;
          -  No other prior malignancy except curatively treated squamous cell or basal cell skin&#xD;
             cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No ongoing infection requiring systemic antibiotics&#xD;
&#xD;
          -  No severe postoperative complication that would preclude study&#xD;
&#xD;
          -  Carcinoembryonic antigen normal&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No other concurrent investigational immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior systemic chemotherapy&#xD;
&#xD;
          -  No other concurrent investigational chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent steroids&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy&#xD;
&#xD;
          -  No concurrent investigational radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent investigational surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 3 weeks since prior systemic antibiotic therapy of more than 5 days duration&#xD;
             (excluding topical antibiotics or perioperative prophylactic antibiotics)&#xD;
&#xD;
          -  No concurrent cytotoxic immunosuppressive agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael G Hanna Jr., PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Intracel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>John and Dorothy Morgan Cancer Center at Lehigh Valley Hospital</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18105-1556</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Hospital</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2004</verification_date>
  <study_first_submitted>May 6, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>May 29, 2013</last_update_submitted>
  <last_update_submitted_qc>May 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2013</last_update_posted>
  <keyword>stage II colon cancer</keyword>
  <keyword>stage III colon cancer</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>BCG Vaccine</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

